Weiss Ratings Reiterates "Sell (D-)" Rating for XOMA Royalty (NASDAQ:XOMA)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for XOMA Royalty, despite other brokerages like Wall Street Zen and Zacks Research recently upgrading their ratings.
• XOMA Royalty's stock price decreased by 1.7%, reaching $36.54, while the company has a market capitalization of $441.71 million.
• Insider trading activity shows that CFO Thomas M. Burns sold 4,330 shares of the company, reflecting a 12.58% reduction in his holdings.

XOMA Royalty (NASDAQ:XOMA - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other brokerages have also commented on XOMA. Wall Street Zen raised XOMA Royalty from a "hold" rating to a "buy" rating in a research note on Monday, August 11th. Zacks Research raised XOMA Royalty from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, XOMA Royalty presently has an average rating of "Moderate Buy" and an average price target of $69.50.

XOMA Royalty Stock Down 1.7%

Shares of XOMA traded down $0.63 during midday trading on Wednesday, reaching $36.54. 20,645 shares of the stock were exchanged, compared to its average volume of 46,080. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $39.92. The company's 50 day moving average is $33.68 and its two-hundred day moving average is $27.48. The company has a market capitalization of $441.71 million, a P/E ratio of -23.65 and a beta of 1.02. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.60. The business had revenue of $13.13 million during the quarter, compared to the consensus estimate of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. On average, sell-side analysts anticipate that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In other XOMA Royalty news, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the completion of the transaction, the chief financial officer directly owned 30,079 shares of the company's stock, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by corporate insiders.

Institutional Trading of XOMA Royalty

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its stake in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,523 shares during the period. Opaleye Management Inc. boosted its stake in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock worth $6,428,000 after buying an additional 2,044 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in XOMA Royalty in the 2nd quarter valued at about $116,000. Occudo Quantitative Strategies LP acquired a new stake in XOMA Royalty in the 2nd quarter valued at about $527,000. Finally, Marshall Wace LLP lifted its position in XOMA Royalty by 12.2% during the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company's stock worth $411,000 after acquiring an additional 1,775 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.